MNCs Eye Nigeria As Hub Of Africa Making Up For Slow Growth Elsewhere
This article was originally published in PharmAsia News
Several multinational drug makers such as GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer and Sanofi are looking to Africa, Nigeria in particular, for markets to make up for reduced growth in developed countries.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.